Trials / No Longer Available
No Longer AvailableNCT00590915
Erwinase Master Treatment Protocol
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Phoenix Children's Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
The purpose of this study is to make Erwinase available to patients with acute lymphoblastic leukemia (ALL) who have had previous allergic reactions to certain formulations of L-asparaginase.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erwinia L-asparaginase | Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced. NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics. |
Timeline
- First posted
- 2008-01-11
- Last updated
- 2026-01-23
Source: ClinicalTrials.gov record NCT00590915. Inclusion in this directory is not an endorsement.